Cemiplimab (Libtayo, Regeneron Pharmaceuticals ... FRACP, research lead of head and neck cancer and cutaneous squamous cell carcinoma in the department of medical oncology at Peter MacCallum ...
Cemiplimab significantly improves DFS in patients with high-risk CSCC post-surgery, reducing recurrence or death risk by 68% compared with placebo. The C-POST trial marks the first immunotherapy ...
Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback